Alto aims for $101M IPO to pave neuro development climb
Alto Neuroscience is looking to raise roughly $101 million from an initial public offering, the company disclosed Monday.
Alto Neuroscience is looking to raise roughly $101 million from an initial public offering, the company disclosed Monday.
Arcus Biosciences and Gilead Sciences are rethinking their TIGIT strategy. Gilead is stopping a phase 3 lung cancer TIGIT clinical trial—and walking away from another project—but reaffirming its commitment to Arcus by pumping a further $320 million into the biotech.
Sarepta Therapeutics’ next Duchenne muscular dystrophy (DMD) med seems to be doing the job of spurring dystrophin expression. But do any of the data for SRP-5051 matter given the recent approval of the biotech’s gene therapy for the same condition, Elevidys?
Shanghai-based biotech Laekna’s oral cancer drug afuresertib has failed to significantly improve progression-free survival for ovarian cancer patients in a phase 2 trial.
Ascendis Pharma and Frazier Life Sciences have spun out the former’s oncology assets into a new biotech, backed by the likes of RA Capital, HealthQuest Capital and venBio.
Cleveland Diagnostics, maker of a prostate cancer screening test, has raised more than $75 million in growth capital funds to expand its approach to additional tumors.
With last week seeing back-to-back oversized biotech IPOs to kick off the new year, it’s no surprise that Fractyl Health is now kicking its own offering plans up a gear.
Decentralized trials provider Science 37 has agreed to be acquired by telehealth and diagnostics company eMed in an all-cash tender offer valued at around $38 million.
Roche has waved goodbye to one of its KRAS prospects, terminating an alliance with Hookipa Pharma 15 months after betting $25 million on its novel approach to the oncogene. Shortly after receiving the news, Hookipa decided to lay off 30% of its employees and focus on a slimmed-down list of candidates.
Sanofi is paying $40 million to add another cytokine—IL-10—to its hit list. The upfront fee has secured the French drugmaker the chance to work with Synthekine to overcome long-standing barriers to the use of the cytokine in the treatment of inflammatory diseases.